Karen L. Smith - Net Worth and Insider Trading
Karen L. Smith Net Worth
The estimated net worth of Karen L. Smith is at least $2 Million dollars as of 2024-11-12. Karen L. Smith is the Global Head of R&D and CMO of Jazz Pharmaceuticals PLC and owns about 14,182 shares of Jazz Pharmaceuticals PLC (JAZZ) stock worth over $2 Million. Karen L. Smith is also the Director of Acceleron Pharma Inc and owns about 1,622 shares of Acceleron Pharma Inc (XLRN) stock worth over $289,933. Details can be seen in Karen L. Smith's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Karen L. Smith has not made any transactions after 2021-04-05 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Karen L. Smith
Karen L. Smith Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Karen L. Smith owns 9 companies in total, including Antares Pharma Inc (ATRS) , Emergent BioSolutions Inc (EBS) , and Sangamo Therapeutics Inc (SGMO) among others .
Click here to see the complete history of Karen L. Smith’s form 4 insider trades.
Insider Ownership Summary of Karen L. Smith
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ATRS | Antares Pharma Inc | 2022-05-24 | director |
| EBS | Emergent BioSolutions Inc | 2020-05-21 | EVP & Chief Medical Officer |
| SGMO | Sangamo Therapeutics Inc | 2018-06-26 | director |
 | | 2021-04-05 | director |
| | 2016-08-12 | Global Head of R&D and CMO |
| | 2018-02-13 | director |
| | 2022-05-16 | director |
| | 2022-05-19 | Chief Medical Officer |
| | 2023-08-18 | director |
Karen L. Smith Latest Holdings Summary
Karen L. Smith currently owns a total of 2 stocks. Among these stocks, Karen L. Smith owns 14,182 shares of Jazz Pharmaceuticals PLC (JAZZ) as of August 12, 2016, with a value of $2 Million and a weighting of 86.2%. Karen L. Smith also owns 1,622 shares of Acceleron Pharma Inc (XLRN) as of April 5, 2021, with a value of $289,933 and a weighting of 13.8%.
Latest Holdings of Karen L. Smith
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals PLC | 2016-08-12 | 14,182 | 127.74 | 1,811,609 |
| XLRN | Acceleron Pharma Inc | 2021-04-05 | 1,622 | 178.75 | 289,933 |
Holding Weightings of Karen L. Smith
Karen L. Smith Form 4 Trading Tracker
According to the SEC Form 4 filings, Karen L. Smith has made a total of 0 transactions in Jazz Pharmaceuticals PLC (JAZZ) over the past 5 years. The most-recent trade in Jazz Pharmaceuticals PLC is the acquisition of 608 shares on August 12, 2016, which cost Karen L. Smith around $83,357.
According to the SEC Form 4 filings, Karen L. Smith has made a total of 2 transactions in Acceleron Pharma Inc (XLRN) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Acceleron Pharma Inc is the sale of 11,864 shares on April 5, 2021, which brought Karen L. Smith around $2 Million.
Insider Trading History of Karen L. Smith
- 1
Karen L. Smith Trading Performance
GuruFocus tracks the stock performance after each of Karen L. Smith's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Karen L. Smith is -16.93%. GuruFocus also compares Karen L. Smith's trading performance to market benchmark return within the same time period. The performance of stocks bought by Karen L. Smith within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Karen L. Smith's insider trading performs compared to the benchmark.
Performance of Karen L. Smith
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -6.46 | | | | | |
| Relative Return to S&P 500(%) | -7.74 | | | | | |
Karen L. Smith Ownership Network
Ownership Network List of Karen L. Smith
Ownership Network Relation of Karen L. Smith
Karen L. Smith Owned Company Details
What does Antares Pharma Inc do?
Who are the key executives at Antares Pharma Inc?
Karen L. Smith is the director of Antares Pharma Inc. Other key executives at Antares Pharma Inc include See Remarks Peter C Richardson , Executive Vice President & CFO Fred M Powell , and See Remarks Peter J Graham .
Antares Pharma Inc (ATRS) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Antares Pharma Inc (ATRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Antares Pharma Inc (ATRS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Antares Pharma Inc (ATRS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Antares Pharma Inc Insider Transactions
Karen L. Smith Mailing Address
Above is the net worth, insider trading, and ownership report for Karen L. Smith. You might contact Karen L. Smith via mailing address: C/o Jazz Pharmaceuticals Plc, 5th Fl, Waterloo Exchange, Waterloo Rd, Dublin L2 4 L2.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
